8 results about "Eotaxin" patented technology

The present disclosure relates to a biomarker for distinguishing between depression and bipolar disorder and uses thereof, elucidating a composition for distinguishing between depression and bipolar disorders and a method for providing information for distinguishing between depression and bipolar disorder, using same, wherein the composition is based on a biomarker composition comprising eotaxin, nerve growth factors (NGF), tumor necrosis factor-α (TNF-α), glial cell derived neurotrophic factor (GDNF), interleukin-1β (IL-1β), and serum soluble CD40 Ligand (sCD40L) within a serum sample and includes an agent for measuring the expression level of each of the six biomarker proteins.

The invention relates to a biomarker for distinguishing depression and bipolar affective disorder and application thereof, in particular to a composition for distinguishing depression and bipolar affective disorder, a method for providing information for distinguishing depression and bipolar affective disorder through the composition and the like, and the composition comprises a preparation. The preparation detects the expression level of each of six proteins of a biomarker based on a biomarker composition for distinguishing depression from bipolar affective disorder, and the biomarker composition comprises an eosinophilic granulocyte chemokine (Eotaxin), a nerve growth factor (NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF, NGF and NGF in a serum sample. The invention relates to a tumor necrosis factor-alpha (tumor necrosis factor-alpha, TNF-alpha), a glial cell derived neurotrophic factor (GDNF), an interleukin-1beta (interleukin-1beta, IL-1beta), and a serum soluble CD40 ligand (sCD40L), in particular to a tumor necrosis factor-alpha (tumor necrosis factor-alpha, TNF-alpha), a glial cell derived neurotrophic factor (GDNF), an interleukin-1beta (interleukin-1beta, IL-1beta), a tumor necrosis factor-alpha (tumor necrosis factor-alpha, TNF-alpha) and a serum soluble CD40 ligand (sCD40L).

The application provides a multiple trauma early warning marker combination and application and product, and belongs to the biomarker field.The application provides a marker combination for multiple trauma early warning, which comprises Eotaxin, MCP-4, IP-10, IL-18 and MCP-1, and through detection and interpretation of Eotaxin, MCP-4, IP-10, IL-18 and MCP-1 in serum, multiple trauma combined with MODS and prognosis can be predicted.The detection reagent for Eotaxin, MCP-4, IP-10, IL-18 and MCP-1 detection can be used for preparing a kit for predicting multiple trauma combined with MODS and prognosis, and is simple, efficient and low in cost.

The invention provides a multi-trauma early warning marker combination as well as application and a product thereof, and belongs to the field of biomarkers. The invention provides a marker combination for early warning of multiple wounds, the marker combination comprises Eotaxin, MCP-4, IP-10, IL-18 and MCP-1, the Eotaxin, the MCP-4, the IP-10, the IL-18 and the MCP-1 in serum are detected and interpreted, and the multiple wounds combined with MODS and prognosis are predicted. The detection reagent for detecting Eotaxin, MCP-4, IP-10, IL-18 and MCP-1 can be used for preparing a kit for predicting multiple wounds with MODS and prognosis, is simple and efficient, and reduces the cost.

A method of treating preterm birth (PTB) risk in a subject is disclosed. An example method may obtain risk indicator values for two or more risk indicators selected from a panel of risk indicators comprising the group consisting of: AFP, anemia status, assistance status, body mass index, CD40L, cholesterol, CRP, diabetes status, ENA78, EOTAXIN, GP130, hCG, HDL, HGF, hypertension status, ICAM1, IFNA, IFNB, IL-10, IL-13, Il-15, IL-1A, IL-1RA, IL-4, IL-5, IL-6, IL-7, IL-8, IL1R1, IL4R, INH, IP-10, LDL, LIF, MCP3, MCSF, MIG, MIP1A, MIP1B, NGF, PAPP-A, parity, PDGFBB, progesterone, RANTES, ratio of triglycerides to HDL, sFASL, TNFR1, TRAIL, triglycerides, VEGF, VEGFR1, VEGFR2, and VEGFR3. The example method may input the obtained risk indicator values into a predictive model to calculate a predictive score indicative of PTB risk, determine the subject has an elevated risk of PTB risk based upon the predictive score, and administer an intervention to the subject.

This invention provides an immunomodulatory factor, its preparation method, and its application. The immunomodulatory factor includes: Eotaxin-2, I-309, IL-12p40, IL-12p70, MIG, MIP-1a, TNF-α, AR, BDNF, bFGF, EGF-R, EG-VEGF, IGFBP-6, VEGF, NAP-2, PF4, Activin A, ANG-1, DAN, Follistatin, Galectin-7, ICAM-2, etc. The immunomodulatory factor can be used to prepare immunomodulators, cancer intervention agents, etc., and is of great significance for research on the mechanisms by which thymic mitochondria regulate anti-tumor immunity, including influencing immune cell metabolism, signal transduction, apoptosis, and immune escape.

The invention relates to a method of collecting information useful in aiding diagnosis of an oesophageal disease in a subject comprising: providing a sample from said subject, wherein said sample comprises cells collected from the surface of the subject's oesophagus; contacting said sample with an aqueous fluid; taking an aliquot of said aqueous fluid; assaying said aliquot of aqueous fluid to determine the presence of one or more soluble biomarker(s). The invention provides sets of biomarkers for different applications. For Barrett's Oesophagus (BE), preferred biomarkers are TFF3, REG4, FABP2, MEP1A, CXCL8; and SPINK4. For Eosinophilic Oesophagitis (EOE) preferred biomarkers are C-kit, Eotaxin-3, IL-5, IL-13, IL-33, IL-25; and Eotaxin-2. The invention also provides uses, apparatus and kits.

An object of the present invention is to provide a mesenchymal stem cell having excellent cell adhesiveness and capable of obtaining a sufficient cell proliferation rate without requiring a serum medium.SOLUTION: The present invention relates to a mesenchymal stem cell in which a production amount of a granulocyte colony-stimulating factor (G-CSF) is enhanced. The present invention also includes a mesenchymal stem cell in which a production amount of at least one selected from the group consisting of eotaxin, fractalkine, GRO, MCP-3, and VEGF is enhanced.SELECTED DRAWING: None